Kezar Life Sciences, Inc. — Director's Dealing 2018

Jun 28, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kezar Life Sciences, Inc. (KZR)
CIK: 0001645666
Period of Report: 2018-06-25

Reporting Person: BAY CITY CAPITAL LLC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-06-25	Common Stock	C	472229	—	Acquired	472229	Indirect
2018-06-25	Common Stock	P	150000	$15.00	Acquired	622229	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-25	Series B Redeemable Convertible Preferred Stock	$	C	472229	Disposed		Common Stock (472229)	Indirect

Footnotes

F1: Each share of Series B Redeemable Convertible Preferred Stock was convertible into one share of Common Stock at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering.

F2: Bay City Capital LLC, a Delaware limited liability company (BCC), Bay City Capital JV Management I LLC, a Delaware limited liability company (Management I), Bay City Capital GF XINDE Investment Management Co., a Cayman Islands company (Management Co.), and Bay City Capital GF Xinde International Life Sciences USD Fund, L.P., a Cayman Islands exempt limited partnership (USD Fund) are deemed to be a group for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management Co. is the general partner of USD Fund and has voting and dispositive power with respect to the securities held by USD Fund. BCC is the manager of, and an advisor to, Management I, and Management I holds an equity interest in Management Co.

F3: Represent securities held by USD Fund, including indirect interests of BCC, Management I, and Management Co. BCC, Management I and Management Co. each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein.